Standpoint Research downgrades AstraZeneca plc (NYSE: AZN) from Buy to Hold.

The firm said, "There is still value ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE